News
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
Context Therapeutics® and Jefferson Health Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Advanced Endometrial Cancer
Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Antiestrogen to Determine Potential of Complete Hormone Blockade on Endometrial Cancer Outcomes